Navigation Links
BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
Date:8/13/2014

BOULDER, Colo., Aug. 13, 2014 /PRNewswire/ -- BiOptix announced today an additional $1.4M financing from existing investors.  The funds will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand. 

Rick Whitcomb, President and CEO of BiOptix, noted:  "This latest increase in capital shows that our investors are confident in our plan and our team, and that BiOptix is on a solid path to commercial success."  BiOptix continues to see opportunity in the label-free marketplace, which is looking for a high quality, high performance SPR instrument at a reasonable price. "We are making great inroads in the marketplace, and this infusion of capital will aid our efforts to reach as many scientific researchers as possible," commented Whitcomb.

Surface Plasmon Resonance (SPR) is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix marries the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces expansion of Innovators Program into Europe
2. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
3. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
4. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
5. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
6. Perrigo Company plc Announces Quarterly Dividend
7. Kindred Biosciences Announces Second Quarter 2014 Financial Results
8. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
9. WuXi PharmaTech Announces Second-Quarter 2014 Results
10. Nutrastar International Inc. Announces Second Quarter 2014 Results
11. Novogen Announces Results of General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):